[APTO] Aptose Biosciences, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.39 Change: 0.18 (14.88%)
Ext. hours: Change: 0 (0%)

chart APTO

Refresh chart

Description: Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company?s pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company?s discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.3 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.92
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities6.8 M Cash From Investing Activities-5.09 M Cash From Operating Activities-6.72 M Gross Profit
Net Profit-7.77 M Operating Profit-7.99 M Total Assets31.6 M Total Current Assets31.4 M
Total Current Liabilities2.33 M Total Debt410 K Total Liabilities2.33 M Total Revenue
Technical Data
High 52 week4.5 Low 52 week1.61 Last close2.09 Last change2.96%
RSI54.43 Average true range0.12 Beta0.94 Volume383.13 K
Simple moving average 20 days1.26% Simple moving average 50 days3.98% Simple moving average 200 days-23.24%
Performance Data
Performance Week-4.13% Performance Month12.97% Performance Quart10% Performance Half-23.72%
Performance Year-30.1% Performance Year-to-date2.96% Volatility daily3.64% Volatility weekly8.15%
Volatility monthly16.7% Volatility yearly57.84% Relative Volume174.06% Average Volume288.05 K
New High New Low


2019-12-09 11:00:10 | Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

2019-12-07 11:00:10 | Aptose Presents Highlights From Corporate Event At ASH

2019-12-04 07:30:10 | Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

2019-12-02 07:30:10 | Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

2019-11-11 08:26:13 | Is Aptose Biosciences TSE:APS In A Good Position To Deliver On Growth Plans?

2019-11-07 07:30:00 | Aptose to Present at BIO-Europe Conference

2019-11-06 09:54:13 | Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

2019-11-05 16:02:00 | Aptose Reports Results for the Third Quarter Ended September 30, 2019

2019-10-22 07:00:05 | Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

2019-10-10 07:30:00 | Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology ESH

2019-09-16 07:30:00 | Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

2019-09-12 06:46:49 | How Much Are Aptose Biosciences Inc. TSE:APS Insiders Spending On Buying Shares?

2019-08-06 16:00:00 | Aptose Reports Results for the Second Quarter Ended June 30, 2019

2019-07-30 07:30:00 | Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

2019-07-23 07:30:00 | Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

2019-07-16 07:05:00 | Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

2019-07-08 10:24:02 | The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu

2019-07-05 08:38:12 | Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks

2019-06-14 07:00:00 | Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

2019-06-04 16:02:00 | Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

2019-06-03 09:00:00 | Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer

2019-06-03 08:38:27 | Aptose Announces Closing of Public Offering of Common Shares

2019-05-31 08:00:00 | Aptose to Present at the Jefferies 2019 Healthcare Conference

2019-05-30 09:01:53 | Aptose Announces Pricing of Public Offering of Common Shares

2019-05-29 16:22:16 | Aptose Announces Proposed Public Offering of Common Shares

2019-05-24 17:43:26 | Aptose Biosciences Establishes New At-The-Market Facility

2019-05-16 10:02:17 | Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association

2019-05-13 08:15:00 | Aptose to Present at May Investor Conferences

2019-05-10 19:24:46 | Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

2019-05-07 17:25:26 | Aptose Biosciences: 1Q Earnings Snapshot

2019-05-07 16:01:00 | Aptose Reports Results for the First Quarter Ended March 31, 2019

2019-04-24 07:30:00 | Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019

2019-04-23 07:30:00 | Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019

2019-04-02 07:00:00 | Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference

2019-03-25 07:02:00 | Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806

2019-03-12 17:18:29 | Aptose Biosciences: 4Q Earnings Snapshot

2019-03-12 16:02:00 | Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018

2019-03-07 07:00:00 | Aptose to Participate in Upcoming Investor Conferences in March 2019

2019-03-04 07:00:00 | Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806

2019-02-28 07:00:00 | Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting

2019-02-26 07:30:00 | Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019

2019-02-25 07:00:00 | Aptose Biosciences Submits IND Application for CG-806

2019-02-21 08:55:01 | Will Difficult Comparison Hurt Bio-Rad's BIO Q4 Earnings?

2019-02-20 08:54:01 | Will Hospice Strength Show on Amedisys' AMED Q4 Earnings?

2019-02-19 07:30:00 | Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-01-02 07:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within The TJX Companies, Nasdaq, Werner Enterprises, Global Ship Lease, Domo, and Aptose Biosciences — New Research Emphasizes Economic Growth

2019-01-02 07:05:00 | Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference

2018-12-24 06:12:11 | Aptose Biosciences Sees Hammer Chart Pattern: Time to Buy?

2018-12-12 10:00:00 | Aptose Presents Highlights From CG-806 KOL Event

2018-12-03 07:10:00 | OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting